CopyMark Law Group
4.9/5
Drawing for PR

USPTO serial 79397083

PR

Reviewed by CopyMark Law Group

Reg. 7717932Status 700Registered
Filing date
Status date
Registration date
Mar 11, 2025
Examiner
SEVERSON, JUSTIN
Law office
GENERIC WEB UPDATE

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with PR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Esther Kim

PO Box 660122BS2404TP-013 / SBTUS240288Arcadia, CA 91066

Goods and services

ClassDescriptionStatusFirst use
001Bases being chemical preparations of pharmaceutical drug product formulation, manufacturing, packing, testing and release to market; salts being chemical preparations for improved therapeutic actions, additional indication, drug product stability enhancement and bioavailability improvement in pharmaceutical products; cellulose derivatives being chemical preparations for use as excipients in drug formulation, providing controlled release and delayed release of drug enhancing bioavailability of drug product; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; animal extracts in the nature of from bovine source for use in pharmaceutical and nutraceutical manufacturing, particularly in dietary supplements and therapeutic drug products as well as nutritional products for the food industry; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; plant extracts, other than essential oils, for use in the manufacture of pharmaceuticals; plant extracts, other than essential oils, for use in the manufacture of cosmeticsACTIVE—
005Immunological products for intravenous injections, namely for immune system support, such as vaccines, monoclonal antibodies (mAbs), Cytokines/Cytokine Inhibitors; tablets for medicines, specifically diuretic, anti-fungal, digestive disorders, anti-inflammatory, antidiabetic, dementia tablets for treating common infections and chronic diseases; drinking water fused with electrolytes, salts, hemodialysis solution, suitable for rehydration and maintenance therapy for medical purposes; gelatin capsules sold empty for pharmaceuticals; slimming pills; medicinal ointments for treating skin conditions, such as dermatitis, wounds, or burns, offering antiseptic and healing properties; medicines for human purposes for treating various ailments ranging from cough and cold medicines to cardiac disease; Nutraceutical preparations for therapeutic or medical purposes for treating digestive disorders, vitamin deficiency, therapeutic dosage of Vitamins; biochemical medicines for treating metabolic disorders, hormonal imbalances, autoimmune diseases, and rare genetic conditions, such as enzyme replacement therapies, peptide-based drugs, and nucleotide-based therapies; pharmaceutical preparations for treating heart diseases, asthma, obesity, diabetes, hypertensionACTIVE—
035Import-export agency services; business management consultancy; outsourcing services; business research; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical suppliesACTIVE—
040Custom assembling of materials for others, namely, multi-layer coated tablets, liquid filled hard gelatin capsules, bottle filling activities; providing information relating to material treatment; processing of metal surfaces using precision grinding techniques; irradiation of food; cryopreservation services; food and drink processing for others; processing of chemicals; sorting of waste and recyclable material; bookbinding; grindingACTIVE—
042Technological research in the field of formulation development, scale-up batches, formulation refinement, drug delivery systems, and optimization of production processes; conducting technical project studies, namely, bioequivalence studies, clinical trial study design and regulatory compliance research in the pharmaceutical field; scientific laboratory services; providing scientific information, advice and consultancy relating to carbon offsetting; quality control for others; industrial inspection serialization of products, medical devices; quality assessment of pharmaceutical manufacturing processes, process validation, focusing on batch consistency, contamination control, impurity profiling and GMP compliance; biological research; Medical and scientific research, namely, conducting clinical trials for others; medical researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 22, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Nov 5, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 5, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Oct 18, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 25, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 24, 2025FIMPFINAL DISPOSITION PROCESSED—
Jun 12, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 11, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 11, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 21, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 21, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 15, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 10, 2025ISCRWITHDRAWN FROM ISSUE - OG REVIEW QUERY—
Dec 27, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 21, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 21, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 21, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 19, 2024RFNTREFUSAL PROCESSED BY IB—
Oct 2, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 2, 2024RFRRREFUSAL PROCESSED BY MPU—
Sep 27, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 26, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 25, 2024DOCKASSIGNED TO EXAMINER—
Jun 10, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 10, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 6, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance